Disc Medicine (NASDAQ:IRON) Price Target Raised to $132.00

Disc Medicine (NASDAQ:IRON - Free Report) had its price target upped by Cantor Fitzgerald from $99.00 to $132.00 in a report issued on Tuesday, Marketbeat reports. Cantor Fitzgerald currently has an overweight rating on the stock.

Several other equities analysts have also issued reports on IRON. Stifel Nicolaus raised their price objective on Disc Medicine from $90.00 to $94.00 and gave the stock a "buy" rating in a report on Friday, January 24th. HC Wainwright restated a "buy" rating and set a $118.00 price target on shares of Disc Medicine in a research note on Tuesday, January 21st. Scotiabank boosted their price objective on Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a research note on Monday, March 3rd. Morgan Stanley reissued an "overweight" rating and issued a $85.00 price objective on shares of Disc Medicine in a report on Friday, March 7th. Finally, TD Cowen initiated coverage on shares of Disc Medicine in a report on Thursday, February 27th. They issued a "buy" rating on the stock. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $93.80.

Disc Medicine Price Performance

Shares of IRON traded down $0.99 during mid-day trading on Tuesday, reaching $52.24. The company's stock had a trading volume of 1,082,703 shares, compared to its average volume of 360,421. The company's 50 day moving average is $55.26 and its 200 day moving average is $56.02. The stock has a market cap of $1.81 billion, a PE ratio of -13.13 and a beta of 0.73. Disc Medicine has a 12-month low of $25.60 and a 12-month high of $68.73.

Remove Ads

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, topping analysts' consensus estimates of ($1.06) by $0.08. As a group, sell-side analysts anticipate that Disc Medicine will post -4.07 EPS for the current fiscal year.

Insider Buying and Selling at Disc Medicine

In other news, CEO John D. Quisel sold 13,012 shares of the business's stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $61.95, for a total transaction of $806,093.40. Following the transaction, the chief executive officer now directly owns 72,065 shares in the company, valued at $4,464,426.75. The trade was a 15.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Rahul Khara sold 7,500 shares of the firm's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $62.75, for a total transaction of $470,625.00. Following the completion of the sale, the insider now owns 14,035 shares of the company's stock, valued at approximately $880,696.25. The trade was a 34.83 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 396,284 shares of company stock valued at $21,865,764. 4.24% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Sterling Capital Management LLC boosted its position in shares of Disc Medicine by 798.4% during the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock worth $36,000 after purchasing an additional 503 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Disc Medicine in the fourth quarter valued at about $40,000. Tower Research Capital LLC TRC boosted its holdings in Disc Medicine by 47.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock worth $52,000 after buying an additional 266 shares in the last quarter. Quest Partners LLC acquired a new position in Disc Medicine during the third quarter worth about $131,000. Finally, Quantbot Technologies LP purchased a new position in Disc Medicine in the third quarter valued at about $146,000. Institutional investors and hedge funds own 83.70% of the company's stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.